Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre.
Jacopo MansoYi Hang ZhuMonica MargoniFrancesca RinaldiSimona CensiSofia CarducciChiara CosmaMario PlebaniPaolo GalloCaterina MianPublished in: Clinical endocrinology (2021)
TRAb levels measured with commercial automatic methods at the time of a patient being diagnosed with alemtuzumab-induced GD emerged as a novel biomarker for predicting a fluctuating disease phenotype, with an influence on subsequent therapeutic decisions and patients' follow-up.